Ajanta Pharma Limited
Add to watch list to get report alerts
BSE Code:
532331
NSE Code:
AJANTPHARM
Business Profile
Business Profile
Ajanta Pharma (AJANTAPH) was incorporated on December 31, 2007 as a private company and went public on July 7, 1986. It is a global pharmaceutical company with capabilities in the areas of product research, manufacturing and marketing. The chairman of AJANTAPH is Mannalal B. Agrawal and Purushottam B. Agrawal is the managing director.
Ajanta Pharma manufactures a wide range of therapeutic products covering segments like anthelmintics, anti-histaminics, antibiotics, cardiovasculars and anti-TB among others. Brands include Uniminth, Apmox, Apectrolyte etc. Ajanta Pharma has set up world-class manufacturing facilities in India, Mauritius and Turkmenistan that are equipped with state-of-the-art infrastructure. The company is to set up a pharmaceutical and biotech special economic zone (SEZ) and export oriented unit (EOU) in Aurangabad, Maharashtra. It is investing about Rs 1 billion to upgrade one of its manufacturing facilities in Aurangabad to US FDA standards and to expand its R&D facilities for US markets.
AJANTAPH `s subsidiaries are Ajanta Pharma (Mauritius) and Ajanta Pharma USA LLC. It has a joint venture with Turkmenderman Ajanta Pharma in Turkmenistan. The company signed an agreement to license out technology for its highly successful anti-scar product Vaniza to Orient Europharma (OE), one of the leading pharmaceutical companies of Taiwan. It markets nature-based OTC products to many international markets and supplies medicines to various government institutions like health departments, defence and hospitals in India. The company exports to over 50 countries spanning across Asia, Africa, Latin America, the Commonwealth of Independent States and Europe. Exports account for more than 60% of sales.
The registered and corporate offices of AJANTAPH are located at Mumbai, India.
Financials
Ajanta Pharma registered a 54.06% growth in net profits to Rs 43.23 million for the quarter ended in September 2008 from a profit of Rs 28.06 million for the quarter ended in September 2007.Net Sales quarter rose 24.22% to Rs 871.61 million for the quarter ended September 2008 from Rs 701.65 million for the quarter ended September 2007.Total income rose 24.06% to Rs 871.61 million for the quarter ended September 2008, from Rs 702.573 million for the quarter ended September 2007. The earnings per share (EPS) of the company stood at quarter Rs 3.69 in the quarter ended September 2008.
Recent Developments
27-FEB-08
Ajanta Pharma is planning to invest Rs 600 million to expand its research and development division and manufacturing facilities. The manufacturing capacity at Paithan in Maharashtra will be doubled at a cost of Rs 350 million. The research and development facility will be upgraded at a cost of Rs 250 million by mid 2008. The company has also set up manufacturing facilities in Mauritius and Turkmenistan.
24-JAN-08
Ajanta Pharma has tied up with Prollenium Medical Technologies (PMT) for an exclusive in-licensing arrangement to market Revanesse in India. Revanesse is PMT's aesthetic dermal filler for use by the dermatology segment.
14-JAN-08
Ajanta Pharma has been conferred with "Quality Excellence Award 2007 ? Silver" (in the category of formulation units with annual turnover of more than Rs 1000 million) by Indian Drug Manufacturers' Association (IDMA). The award is in recognition of Company's excellence in quality, production, material management, utility, personnel and safety systems followed at its manufacturing facility at Paithan near Aurangabad.The Company's manufacturing facility at Paithan has received approvals from FDAs of various countries like Sudan, Libiya, Brazil, Jordan, Uganda, and Tanzania as well as various NGOs.
13-SEP-07
Ajanta Pharma has stepped into an agreement with Prollenium Medical Technologies, Canada to market its highly successful Dermal Filler ``Revanesse`` in India. The company is well established in Therapeutic segments like dermatology, cardiology, and ophthalmology with many first- to -market brands in India.
Future Plans
The company is looking to enter the lifestyle and chronic segments like CNS and pain management. Ajanta is also looking for tie-ups in contract research and manufacturing, acquisitions and in-licensing opportunities from the US market.